Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis
Itay Lotan, Mark A. Hellmann, Yitzhak Friedman, Hadas Stiebel‐Kalish, Israel Steiner, Adi Wilf‐Yarkoni
Topics & Concepts
TolerabilityMedicineCoronavirus disease 2019 (COVID-19)Adverse effectVaccinationMyasthenia gravisSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pediatrics2019-20 coronavirus outbreakPopulationInternal medicineImmunologyVirologyEnvironmental healthInfectious disease (medical specialty)OutbreakDiseaseSARS-CoV-2 and COVID-19 ResearchMyasthenia Gravis and ThymomaPeripheral Neuropathies and Disorders